Drugs / Putilimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07538206 | Apr 2026 → Apr 2031 expected | head and neck cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07472933 | Aug 2026 → Feb 2028 expected | bile duct cancer | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Putilimab | “An Exploratory Study of Neoadjuvant Vibecortamab Combined With Putilimab in Locally Advanced Laryngeal Cancer - A Single-Arm, Phase II Study” NCT07538206 ↗ |